Pembrolizumab (Keytruda®) for metastatic triple negative breast cancer. HTA ID: 21059

Assessment Status Rapid Review Complete
HTA ID 21059
Drug Pembrolizumab
Brand Keytruda®
Indication In combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) in adults whose tumours express PD-L1 with a combined positive score (CPS) ≥ 10 and who have not received prior chemotherapy for metastatic disease.
Assessment Process
Rapid review commissioned 29/11/2021
Rapid review completed 13/01/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with chemotherapy compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.